Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery

Citation
Bartko, P. E., D. Wiedemann, L. Schrutka, C. Binder, C. G. Santos#Gallego, A. Zuckermann, B. Steinlechner, et al. 2017. “Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery.” Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 6 (8): e005455. doi:10.1161/JAHA.116.005455. http://dx.doi.org/10.1161/JAHA.116.005455.

Published Version
doi:10.1161/JAHA.116.005455

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491906

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery

Philipp E. Bartko, MD, PhD; Dominik Wiedemann, MD; Lore Schrutka, MD; Christina Binder, MD; Carlos G. Santos-Gallego, MD; Andreas Zuckermann, MD; Barbara Steinecker, MD; Herbert Koinig, MD, MBA; Gottfried Heinz, MD; Alexander Niessner, MD, MSc; Daniel Zimpfer, MD; Günther Lauber, MD; Irene M. Lang, MD; Klaus Distelmaier, MD, PhD; Georg Goliasch, MD, PhD

Background—Extracorporeal membrane oxygenation following cardiac surgery safeguards end-organ oxygenation but unfavorably alters cardiac hemodynamics. Along with the detrimental effects of cardiac surgery to the right heart, this might impact outcome, particularly in patients with preexisting right ventricular (RV) dysfunction. We sought to determine the prognostic impact of RV function and to improve established risk-prediction models in this vulnerable patient cohort.

Methods and Results—Of 240 patients undergoing extracorporeal membrane oxygenation support following cardiac surgery, 111 had echocardiographic examinations at our institution before implantation of extracorporeal membrane oxygenation and were thus included. Median age was 67 years (interquartile range 60–74), and 74 patients were male. During a median follow-up of 27 months (interquartile range 16–63), 75 patients died. Fifty-one patients died within 30 days, 75 during long-term follow-up (median follow-up 27 months, minimum 5 months, maximum 125 months). Metrics of RV function were the strongest predictors of outcome, even stronger than left ventricular function ($P < 0.001$ for receiver operating characteristics comparisons). Specifically, RV free-wall strain was a powerful predictor univariately and after adjustment for clinical variables, Simplified Acute Physiology Score-3, tricuspid regurgitation, surgery type and duration with adjusted hazard ratios of 0.41 (95%CI 0.24–0.68; $P = 0.001$) for 30-day mortality and 0.48 (95%CI 0.33–0.71; $P < 0.001$) for long-term mortality for a 1-SD (SD = –6%) change in RV free-wall strain. Combined assessment of the additive EuroSCORE and RV free-wall strain improved risk classification by a net reclassification improvement of 57% for 30-day mortality ($P = 0.01$) and 56% for long-term mortality ($P = 0.02$) compared with the additive EuroSCORE alone.

Conclusions—RV function is strongly linked to mortality, even after adjustment for baseline variables and clinical risk scores. RV performance improves established risk prediction models for short- and long-term mortality. (J Am Heart Assoc. 2017;6: e005455. DOI: 10.1161/JAHA.116.005455.)

Key Words: extracorporeal circulation • extracorporeal membrane oxygenation • right ventricle • right ventricular dysfunction • right ventricular function

Extracorporeal membrane oxygenation (ECMO) is a life-saving method for critically ill patients following cardiovascular surgery.1 Despite growing evidence supporting the use of ECMO therapy,2–4 outcome remains poor, and accurate risk stratification challenging: successful weaning probabilities are as low as 31% depending on the series, and in-hospital fatal events are frequent, resulting in short-term mortalities of up to 84%.5–13 Prior studies have focused on
Impact of the Right Ventricular Performance in ECMO  Bartko et al

Methods

Study Population

Between September 2003 and June 2014, adult patients undergoing venoarterial ECMO therapy after cardiovascular surgery were enrolled in our registry. All patients were recruited at the Vienna General Hospital, a university-affiliated tertiary care center. The study was approved by the Ethics Committee of the Medical University of Vienna and is in line with the Declaration of Helsinki. All patients admitted to the Medical University of Vienna provided written consent at hospital admission. For the echocardiographic analysis only patients who underwent a comprehensive preoperative echocardiographic exam at our institution were selected. Patients undergoing a heart transplant were excluded from further analysis (Figure S1).

Echocardiographic Assessment

Standard echocardiograms were performed using commercially available equipment (Vivid 7 and Vivid 9, GE Healthcare, Chicago, IL; Acuson Sequoia, Siemens, Berlin, Germany). Cardiac morphology was assessed using diameters and areas as well as volumetric measurements in standard 4- and 2-chamber views.37 LV volumes and ejection fraction (EF) were calculated using the biplane Simpson method. RV function was quantified by fractional area change, tricuspid annular peak systolic excursion (TAPSE), and RV longitudinal free-wall strain (RVLS).37,38 Right-to-left ventricle diameter ratio and RV pressure load.20,26-28 In the absence of preexisting RV dysfunction, the compensatory reserve is sufficient to outbalance those stressors, resulting in a low incidence of postoperative right heart failure.29 In patients requiring mechanical circulatory support the compensatory reserve might be exhausted, and the alteration of the hemodynamic load opposed to the heart might set in counterproductively. Metrics of RV function are powerful predictors of outcome in patients with pulmonary hypertension, valvular heart disease, patients undergoing cardiac surgery19,30-32 as well as patients receiving LV assist devices.33,34 Complemental imaging techniques such as speckle-tracking imaging allow detection of even subclinical changes of myocardial function and are readily available. Recent studies suggest that speckle tracking of strain more accurately quantifies RV function as opposed to traditional metrics and improves risk stratification.35,36

What Are the Clinical Implications?

• Although left ventricular function might have only minor impact on outcome, prognosis seems limited if right ventricular performance is already affected preoperatively.
• Further studies are needed to test whether the dismal course can be improved by therapies tailored specifically to the failing right heart.

Methods

Study Population

Between September 2003 and June 2014, adult patients undergoing venoarterial ECMO therapy after cardiovascular surgery were enrolled in our registry. All patients were recruited at the Vienna General Hospital, a university-affiliated tertiary care center. The study was approved by the Ethics Committee of the Medical University of Vienna and is in line with the Declaration of Helsinki. All patients admitted to the Medical University of Vienna provided written consent at hospital admission. For the echocardiographic analysis only patients who underwent a comprehensive preoperative echocardiographic exam at our institution were selected. Patients undergoing a heart transplant were excluded from further analysis (Figure S1).

Echocardiographic Assessment

Standard echocardiograms were performed using commercially available equipment (Vivid 7 and Vivid 9, GE Healthcare, Chicago, IL; Acuson Sequoia, Siemens, Berlin, Germany). Cardiac morphology was assessed using diameters and areas as well as volumetric measurements in standard 4- and 2-chamber views.37 LV volumes and ejection fraction (EF) were calculated using the biplane Simpson method. RV function was quantified by fractional area change, tricuspid annular peak systolic excursion (TAPSE), and RV longitudinal free-wall strain (RVLS).37,38 Right-to-left ventricle diameter ratio and RV pressure load.20,26-28 In the absence of preexisting RV dysfunction, the compensatory reserve is sufficient to outbalance those stressors, resulting in a low incidence of postoperative right heart failure.29 In patients requiring mechanical circulatory support the compensatory reserve might be exhausted, and the alteration of the hemodynamic load opposed to the heart might set in counterproductively. Metrics of RV function are powerful predictors of outcome in patients with pulmonary hypertension, valvular heart disease, patients undergoing cardiac surgery19,30-32 as well as patients receiving LV assist devices.33,34 Complemental imaging techniques such as speckle-tracking imaging allow detection of even subclinical changes of myocardial function and are readily available. Recent studies suggest that speckle tracking of strain more accurately quantifies RV function as opposed to traditional metrics and improves risk stratification.35,36

What Is New?

• Right ventricular function is a powerful predictor of mortality and improves risk stratification in patients who need venoarterial extracorporeal membrane oxygenation after cardiovascular surgery.

Clinical Perspective

What Is New?

• Right ventricular function is a powerful predictor of mortality and improves risk stratification in patients who need venoarterial extracorporeal membrane oxygenation after cardiovascular surgery.

What Are the Clinical Implications?

• Although left ventricular function might have only minor impact on outcome, prognosis seems limited if right ventricular performance is already affected preoperatively.
• Further studies are needed to test whether the dismal course can be improved by therapies tailored specifically to the failing right heart.

Clinical variables, comorbidities, and renal function for risk stratification before ECMO initiation.1-3,9,10,14-17 However, data on cardiac physiology and myocardial mechanics before therapy—easily assessable by echocardiography—and their predictive value are scarce.

Pre-, and postcardiotomy right ventricular (RV) dysfunction is strongly linked to outcome.18-22 The etiology of RV failure is multifactorial: pericardiotomy results in loss of pericardial support and a decline of myocardial blood flow.23,24 Cardiopulmonary bypass itself may cause an inflammatory response.25 Furthermore, ECMO initiation results in rising afterload increasing left ventricular (LV) end-diastolic pressure and consequently RV pressure load.20,26-28 In the absence of preexisting RV dysfunction, the compensatory reserve is sufficient to outbalance those stressors, resulting in a low incidence of postoperative right heart failure.29 In patients requiring mechanical circulatory support the compensatory reserve might be exhausted, and the alteration of the hemodynamic load opposed to the heart might set in counterproductively. Metrics of RV function are powerful predictors of outcome in patients with pulmonary hypertension, valvular heart disease, patients undergoing cardiac surgery19,30-32 as well as patients receiving LV assist devices.33,34 Complemental imaging techniques such as speckle-tracking imaging allow detection of even subclinical changes of myocardial function and are readily available. Recent studies suggest that speckle tracking of strain more accurately quantifies RV function as opposed to traditional metrics and improves risk stratification.35,36

Left- and Right-Ventricular Longitudinal Strain

LV and RV longitudinal shortening (strain) were measured by tracking the displacement of speckles from 2-dimensional images using an automated algorithm (Speckle tracking).43,44 Longitudinal strain is the percentage shortening of a region of interest relative to its original length.15 This method has been previously shown to provide angle independent and objective quantification of myocardial systolic mechanics.37,38 LV and
RV strain were measured using commercially available software (2D Cardiac Performance Analysis; TomTec Imaging Systems, Munich, Germany) that allows standardized quantification of myocardial strain within 1 platform independently of the echo machine vendor. Files with poor frame rates (<40 fps) and inadequate image quality were excluded from the analyses. Left ventricular longitudinal strain was calculated in standard 4-, 2-, and 3-chamber views as described previously. RVLS strain was assessed in a standard 4-chamber view as described previously. Strain data are expressed as the percentage of systolic shortening, where negative longitudinal deformation corresponds to shortening (contraction) during systole.

**ECMO Management**

Venoarterial ECMO support was initiated in patients with systolic arterial hypotension (<80 mm Hg) or other clinical signs of cardiogenic shock, end-organ failure, or anaerobic metabolism despite optimized supportive therapeutic measures (fluid, inotropes, intra-aortic balloon pump). The ECMO system consisted of a pump console (Bio-Console560, Medtronic, Fridley, MN; or Cardiohelp system, Maquet, Germany) and an inline plasma-tight hollow-fiber microporous membrane oxygenator (Affinity-NTTM, Medtronic, Fridley, MN; or HLS module advanced, Maquet, Germany). All parts of the system were routinely checked every 24 hours by the on-shift intensive care physician or an experienced perfusionist. The complete system was coated with heparin to prevent clotting. If any signs of fibrin deposits or blood clots were present or if blood oxygenation levels declined drastically, the circuit was changed. Ventilator settings were adapted to ensure lung-protective ventilation with peak airway pressures below 25 cm H2O and respiratory tidal volumes between 6 and 8 mL/kg. The fraction of inspired oxygen on the oxygenator was adjusted to maintain a target partial pressure of oxygen of 80 to 100 mm Hg.

**Clinical Definitions and End Points**

The Simplified Acute Physiology Score-3 was recorded; and the European System of Cardiac Operative Risk Evaluation (EuroSCORE) was assessed in every patient at intensive care unit admission. All-cause 30-day mortality was selected as primary end point, and all-cause long-term mortality was defined as death occurring throughout the entire follow-up duration of a median of 27 months (minimum 5 months, maximum 125 months) as a secondary end point. Mortality data were obtained by screening the national registry of deaths including screening for the cause of death (according to the International Classification of Diseases, 10th Revision).

**Statistical Methods**

Discrete data were presented as count and percentage and analyzed by using chi-squared tests. Continuous data were presented as median and interquartile range (IQR) and compared using Kruskal-Wallis tests. Cox proportional hazard regression analysis was applied to assess the effect of the respective echocardiographic parameters on survival. Results were expressed as the hazard ratio (HR) for a 1-SD change with the respective 95% CIs. To account for potential confounders, we adjusted for age, sex, Simplified Acute Physiology Score-3, TR, type of cardiovascular surgery, and procedure duration. Statistical significance was given if 2-sided P<0.05. Kaplan-Meier analysis was applied to evaluate the effect of RV free-wall strain and TAPSE on survival and compared them using a log-rank test. The respective variables were divided into 2 groups using the median of the respective variable as a cutoff value. The discriminatory power of the respective variables was assessed using receiver operating characteristic analysis and Harrell C-statistic. Receiver operating characteristic analysis was used to assess the predictive accuracy of the parameters to predict short- and long-term survival. An improvement in individual risk prediction was examined by the net reclassification improvement. Intraobserver, and interobserver variability for RVLS and TAPSE were assessed in 20 randomly selected patients. Interobserver agreement and intraobserver consistency were presented by using interclass correlation coefficients and a 95% CI. All statistical analyses were computed using the STATA11 software package and SPSS 23.

**Results**

**General Characteristics**

Between September 2003 and June 2014, we included 240 consecutive patients undergoing venoarterial ECMO support following cardiovascular surgery as previously described. Of these, 51 patients underwent cardiac transplantation and were therefore not eligible for study inclusion. A total of 111 patients had preoperative echocardiographic exams at our institution before ECMO therapy and were therefore included in our analysis (Figure S1). The median EuroSCORE of the echocardiographic study population was 11 points (8-13), and the median age was 67 years (IQR 60-74), respectively. Detailed baseline characteristics for the entire study population as well as the echocardiographic study population are displayed in Table 1. Valve surgery was performed in 44 (40%) patients, coronary artery bypass graft surgery in 14 (13%), combined coronary artery bypass graft and valve surgery in 36 (32%), ventricular assist device implantation in 8 (7%), aortic reconstruction in 3 (3%), and other cardiovascular surgeries in 6 (5%) patients. Patients undergoing isolated
valve procedures had single-valve procedures done in 52%, 2-valve procedures in 32%, and 3-valve procedures in 16% of the cases. In patients undergoing valve and CABG, single-valve procedures were done in 69%, 2-valve procedures in 22%, and 3-valve procedures in 8% of the cases. ECMO cannulation was femoral (arterial)-femoral (venous) in 47% of patients, subclavian (arterial)-femoral (venous) in 47% of patients, and central (arterial)-femoral (venous) in 14% of patients. ECMO support was initiated due to weaning failure from cardiopulmonary bypass (60%), immediate postoperative cardiogenic shock in the operating room (26%), postoperative bleeding/tamponade with cardiogenic shock (7%), immediate postoperative respiratory failure in the operating room (3%), and miscellaneous conditions (4%). Of the 111 patients included in this analysis, 95 (86%) were (primarily) successfully weaned from VA-ECMO, and 16 (14%) died on VA-ECMO support. Fifty-one (46%) patients died within 30 days after VA-ECMO implantation, and 75 (68%) during long-term follow-up.

Table 1. Baseline Characteristics of the Total ECMO Study Population (n=240) and the Echocardiographic Substudy Population (n=111)

| Baseline Characteristics at Hospital Admission | Total Study (n=240) | Echocardiographic Study Population (n=111) |
|-----------------------------------------------|--------------------|-----------------------------------------|
| Age, y (IQR)                                  | 65 (55-72)         | 67 (60-74)                              |
| Body-mass index, n (IQR)                      | 27 (24-30)         | 27 (24-31)                              |
| Male sex, n (%)                               | 172 (72)           | 74 (67)                                 |
| EuroSCORE (additive), points (IQR)            | 10 (8-13)          | 11 (8-13)                               |
| Procedure duration, h (IQR)                   | 8.0 (6.1-9.4)      | 7.2 (5.3-9.3)                           |
| Hypertension, n (%)                           | 169 (70)           | 83 (75)                                 |
| Diabetes mellitus, n (%)                      | 66 (28)            | 37 (33)                                 |
| Hypercholesterolemia, n (%)                   | 125 (52)           | 60 (54)                                 |
| Coronary artery disease, n (%)                | 124 (52)           | 58 (52)                                 |
| Glucose, mg/dL (IQR)                          | 109 (92-142)       | 112 (93-148)                            |
| Total cholesterol, mg/dL (IQR)                | 143 (104-182)      | 146 (105-182)                           |
| Triglycerides, mg/dL (IQR)                    | 109 (81-156)       | 111 (74-172)                            |
| Creatinine, mg/dL (IQR)                       | 1.3 (1.1-1.8)      | 1.3 (1.0-1.9)                           |
| Estimated GFR, mL/min per 1.73 m² (IQR)       | 51 (39-69)         | 49 (36-70)                              |
| Total bilirubin, mg/dL (IQR)                  | 1.1 (0.6-1.6)      | 0.9 (0.6-1.4)                           |
| ASAT, U/L (IQR)                               | 33 (23-67)         | 34 (25-56)                              |
| ALAT, U/L (IQR)                               | 33 (23-67)         | 26 (18-40)                              |
| γ-GT, U/L (IQR)                               | 54 (32-105)        | 54 (29-102)                             |
| Hemoglobin, mg/dL (IQR)                       | 12.0 (10.1-13.6)   | 11.2 (9.9-13.0)                         |
| Platelets, 1000/µL (IQR)                      | 188 (134-241)      | 186 (136-243)                           |
| C-reactive protein, mg/dL (IQR)               | 1.0 (0.3-4.3)      | 1.3 (0.3-7.6)                           |
| Leukocytes, 1000/µL (IQR)                     | 8.0 (6.1-11.1)     | 8.2 (6.0-12.1)                          |
| Post-ECMO implantation (first 24 h)           |                    |                                        |
| SAPS-3 at ICU admission, n (%)                | 43 (36-51)         | 43 (36-51)                              |
| ECMO flow, L/min (IQR)                        | 3.4 (2.5-4.3)      | 3.0 (2.5-4.0)                           |
| ECMO rotation, rpm (IQR)                      | 3000 (2485-3500)   | 2740 (2270-3420)                        |
| ECMO gas flow, L/min (IQR)                    | 2.5 (2.0-3.0)      | 2.0 (2.0-3.0)                           |
| ECMO FiO₂, % (IQR)                            | 70 (60-100)        | 68 (60-80)                              |
| ECMO duration, median days (IQR)              | 4 (3-7)            | 5 (2-7)                                 |

Counts are given as numbers and percentages. Continuous variables are given as median and interquartile range. ALAT indicates alanine aminotransferase; ASAT, aspartate aminotransferase; ECMO, extracorporeal membrane oxygenation; FiO₂, fraction of inspired oxygen; GFR, glomerular filtration rate; γ-GT, γ-glutamyl transferase; IQR, interquartile range; SAPS-3, simplified acute physiology score 3.
Preoperative Echocardiographic Assessment of the RV

Median RV diameter measured 35 mm (IQR 30-42 mm), and the RV end-diastolic area was 19 cm² (IQR 14-24 cm²). The median systolic pulmonary pressure was estimated as 56 mm Hg (IQR 41-64 mm Hg). RV function was assessed semiquantitatively and using TAPSE (15 mm, IQR 11-18 mm), fractional area change (35%, IQR 27% to 42%), and RV free-wall strain (–14%, IQR –11% to –20%). Detailed results of the echocardiographic subanalysis are presented in Table 2. RV free-wall strain demonstrated good reproducibility with an interclass correlation coefficient for intraobserver variability of 0.98 (95%CI 0.95-0.99) and for interobserver variability of 0.98 (95%CI 0.94-0.99). Comparable results were observed for TAPSE (intraobserver 0.98, 95%CI 0.95-0.99; interobserver 0.97, 95%CI 0.93-0.99).

Table 2. Echocardiographic Characteristics of the Substudy Population (n=111)

| Echocardiographic Study Population (n=111) | Left atrial/ventricular parameters | Right atrial/ventricular parameters |
|------------------------------------------|-----------------------------------|-----------------------------------|
| LA diameter, mm (IQR)                   | 60 (55-68)                        | 58 (52-67)                        |
| IVS thickness, mm (IQR)                 | 14 (12-16)                        | 35 (30-42)                        |
| LVEDD, mm (IQR)                         | 46 (43-54)                        | 19 (14-24)                        |
| LVEDV, mL (IQR)                         | 125 (84-161)                      | 12 (9-16)                         |
| LVESV, mL (IQR)                         | 58 (38-95)                        | 701 (348-700)                     |
| EF, % (IQR)                             | 48 (37-55)                        | 35 (27-42)                        |
| LV function (semiquantitative)          | Moderately reduced, n (%)         | Moderately reduced, n (%)         |
|                                         | 10 (9)                            | 25 (28)                           |
|                                         | Severely reduced, n (%)           | 17 (15)                           |
| LV global longitudinal strain, % (IQR)  | –12 (–9 to –15)                   | 15 (11-18)                        |
| Aortic stenosis (≥moderate), n (%)      | 31 (28)                           | 51 (40)                           |
| Aortic regurgitation (≥moderate), n (%)  | 19 (15)                           |                                  |
| Mitral stenosis (≥moderate), n (%)      | 7 (5)                             |                                  |
| Mitral regurgitation (≥moderate), n (%)  | 51 (40)                           |                                  |
| RV free-wall longitudinal strain, % (IQR)| –14 (–11 to –20)                 |                                  |
| sPAP, mm Hg (IQR)                       | 56 (41-64)                        |                                  |
| Tricuspid regurgitation (≥moderate), n (%)| 43 (39)                          |                                  |

FAC indicates fractional area change; IQR, interquartile range; IVS, interventricular septum; LA, left atrium; LV, left ventricle; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; RA, right atrium; RV, right ventricular; RVCSI, right ventricular contraction pressure index; RVEDA, right ventricle end-diastolic area; RVEDD, right ventricular end-diastolic diameter; RVSA, right ventricular systolic area; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion.

RV Function and Outcome

During a median follow-up time of 27 months (IQR 16-63 months), 75 patients (68%) died. RV function assessed semiquantitatively by TAPSE and by RVLS were significantly associated with 30-day as well as long-term mortality (Tables 3 and 4). The strongest association was found for RVLS with a crude HR of 0.44 (95%CI 0.30-0.66; P<0.001) for 30-day mortality and of a HR of 0.50 (95%CI 0.36-0.69; P<0.001) for long-term mortality. The area under the curve (AUC) for 30-day mortality was 0.76 for RV free-wall strain, 0.75 for TAPSE, and 0.73 for semiquantitative assessment of RV function and remained persistent for long-term mortality with AUCs of 0.74, 0.72, and 0.68, respectively. AUCs for RV free-wall strain indicated significantly stronger risk prediction for 30-day and long-term mortality compared with metrics of LV function (P<0.001 for RV free-wall strain AUCs and LV ejection fraction (LVEF) for both 30-day and long-term mortality, P<0.001 for RV free-wall strain AUCs and left ventricular GLS (global longitudinal strain) for 30-day mortality and P<0.01 for long-term mortality). The effect was even more pronounced after multivariate adjustment with an adjusted HR of 0.41 (95%CI 0.24-0.68; P=0.001) for 30-day mortality and of a HR of 0.48 (95%CI 0.33-0.71; P=0.001) for long-term mortality. Kaplan-Meier analysis confirmed a significant increase of mortality with decreasing RVLS (30-day P=0.001; Figure Panel A; long-term P=0.001) and decreasing TAPSE (30-day P<0.001; Figure Panel B; long-term P<0.001). No association between mortality and parameters of LV function including LV longitudinal strain were observed (Tables 3 and 4).

RV Free-Wall Longitudinal Strain and Risk Prediction

Combined assessment of the additive EuroSCORE and RV free-wall strain led to a substantial improvement of the discriminatory power measured by the Harrel C-statistic of the EuroSCORE for 30-day mortality (EuroSCORE: 0.59 versus EuroSCORE and RV free-wall strain 0.71; P=0.03) and for long-term mortality (EuroSCORE: 0.59 versus EuroSCORE +...
RV free-wall strain 0.70; \( P=0.03 \)). Simultaneous Cox proportional hazards model yielded a crude HR of 0.46 (95%CI 0.31-0.69; \( P<0.001 \); adjusted HR 0.42, 95%CI 0.25-0.69, \( P=0.001 \)) for RV-free-wall strain and a crude HR of 1.06 (95%CI 0.74-1.53; \( P=0.75 \); adjusted HR 0.79, 95%CI 0.44-1.42, \( P=0.43 \)) for the EuroSCORE for 30-day mortality. For long-term mortality, we observed a crude HR of 0.51 (95%CI 0.36-0.71; \( P<0.001 \); adjusted HR 0.48, 95%CI 0.33-0.71, \( P<0.001 \)) for RV-free-wall strain and a HR of 1.19 (95%CI 0.90-1.57, \( P=0.23 \); adjusted HR 0.90, 95%CI 0.59-1.36, \( P=0.61 \)) for the EuroSCORE for

**Table 3. Univariable Cox Proportional Hazard Model of Preoperative Echocardiographic Parameters**

| Parameter                        | SD   | 30-Day Mortality HR (95%CI) | P Value | AUC | Long-Term Mortality HR (95%CI) | P Value | AUC |
|----------------------------------|------|-----------------------------|---------|-----|-------------------------------|---------|-----|
| LVEDV, mL                        | 57   | 0.84 (0.59-1.20)            | 0.34    | 0.59| 0.88 (0.66-1.17)              | 0.37    | 0.55|
| LV function                      | ---  | 0.84 (0.67-1.05)            | 0.13    | 0.59| 0.88 (0.77-1.11)              | 0.40    | 0.52|
| EF, %                            | 13   | 1.37 (0.98-1.92)            | 0.06    | 0.60| 1.19 (0.92-1.55)              | 0.19    | 0.55|
| LV global longitudinal strain, % | 5    | 1.21 (0.88-1.66)            | 0.25    | 0.61| 1.01 (0.81-1.40)              | 0.64    | 0.51|
| RVEDA, cm²                       | 9    | 0.88 (0.60-1.28)            | 0.50    | 0.54| 0.88 (0.66-1.18)              | 0.39    | 0.55|
| RV-LV diameter ratio, n (IQR)    | 0.23 | 1.01 (0.82-1.39)            | 0.63    | 0.55| 0.78 (0.49-1.25)              | 0.31    | 0.53|
| RVCPI, mm x mm Hg (IQR)          | 310  | 0.78 (0.49-1.25)            | 0.31    | 0.60| 0.76 (0.53-1.10)              | 0.16    | 0.56|
| FAC, %                           | 10   | 0.77 (0.53-1.10)            | 0.15    | 0.60| 0.82 (0.61-1.10)              | 0.18    | 0.57|
| RV function                      | ---  | 1.60 (1.25-2.04)            | <0.001  | 0.73| 1.49 (1.22-1.83)              | <0.001  | 0.68|
| TAPSE, mm                        | 5    | 0.51 (0.35-0.73)            | <0.001  | 0.75| 0.54 (0.40-0.72)              | <0.001  | 0.72|
| RV free-wall strain, %           | 6    | 0.44 (0.30-0.66)            | <0.001  | 0.76| 0.50 (0.36-0.69)              | <0.001  | 0.74|
| sPAP, mm Hg                      | 19   | 1.27 (0.94-1.72)            | 0.12    | 0.59| 1.27 (0.97-1.68)              | 0.09    | 0.64|

Hazard ratios (HR) refer to a 1-SD increase/decrease in continuous variables and to a reduction in 1 category of left ventricular/right ventricular function. AUC indicates area under the curve; EF, left ventricular ejection fraction; FAC, fractional area change; IQR, interquartile range; LV, left ventricular; LVEDV, left ventricular end-diastolic diameter; RV, right ventricular function; RVCPI, right ventricular contraction pressure index; RVEDA, right-ventricular end-diastolic area; sPAP, estimated systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion.

**Table 4. Multivariate Cox Proportional Hazard Model of Preoperative Echocardiographic Parameters**

| Parameter                        | SD   | 30-Day Mortality Adjusted HR (95%CI) | P Value | AUC | Long-Term Mortality Adjusted HR (95%CI) | P Value |
|----------------------------------|------|-------------------------------------|---------|-----|----------------------------------------|---------|
| LVEDV, mL                        | 57   | 1.09 (0.68-1.74)                    | 0.74    |     | 0.72 (0.63-1.37)                       | 0.93    |
| LV function                      | ---  | 0.80 (0.58-1.12)                    | 0.17    |     | 0.81 (0.62-1.04)                       | 0.10    |
| EF, %                            | 13   | 1.58 (0.98-2.55)                    | 0.06    |     | 1.35 (0.92-1.98)                       | 0.13    |
| LV global longitudinal strain, % | 5    | 1.44 (0.87-2.39)                    | 0.16    |     | 1.24 (0.82-1.87)                       | 0.31    |
| RVEDA, cm²                       | 9    | 0.93 (0.79-0.93)                    | 0.79    |     | 0.84 (0.57-1.25)                       | 0.82    |
| RV-LV diameter ratio, n (IQR)    | 0.23 | 1.02 (0.75-1.02)                    | 0.89    |     | 1.29 (0.43-3.81)                       | 0.65    |
| RVCPI, mm x mm Hg (IQR)          | 310  | 0.96 (0.55-1.57)                    | 0.87    |     | 0.82 (0.55-1.23)                       | 0.34    |
| FAC, %                           | 10   | 0.85 (0.55-1.31)                    | 0.46    |     | 0.56 (0.62-1.30)                       | 0.56    |
| RV function                      | ---  | 1.51 (1.21-2.03)                    | 0.007   |     | 1.64 (1.26-2.13)                       | <0.001  |
| TAPSE, mm                        | 5    | 0.56 (0.36-0.86)                    | 0.008   |     | 0.51 (0.34-0.75)                       | 0.001   |
| RV free-wall longitudinal strain, % | 6   | 0.41 (0.24-0.68)                    | 0.001   |     | 0.48 (0.33-0.71)                       | <0.001  |
| sPAP, mm Hg                      | 19   | 1.25 (0.86-1.81)                    | 0.25    |     | 1.20 (0.89-1.68)                       | 0.29    |

Hazard ratios (HR) refer to a 1-SD increase/decrease in continuous variables and to a reduction in 1 category of left ventricular/right ventricular function. HRs are adjusted for all variables in the clinical confounder model, ie, age, sex, SAPS-3 score, tricuspid regurgitation, type of cardiovascular surgery, and procedure duration. EF indicates left ventricular ejection fraction; FAC, fractional area change; IQR, interquartile range; LV, left ventricular; LVEDV, left ventricular end-diastolic diameter; RV, right ventricular function; RVCPI, right ventricular contraction pressure index; RVEDA, right-ventricular end-diastolic area; SAPS-3, simplified acute physiology score-3; sPAP, estimated systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion.
long-term mortality. Furthermore, an improvement in individual risk stratification with combined assessment of the additive EuroSCORE and RV free-wall strain with a net reclassification improvement of 57% for 30-day mortality ($P=0.01$) and 56% for long-term mortality ($P=0.02$) were observed.

Discussion

In this study we show the vital importance of RV function in patients undergoing ECMO support following cardiovascular surgery. Metrics of RV function are strong predictors of short-term and long-term mortality in this vulnerable patient population. These strong associations persist even after adjustment for baseline clinical variables, surgical or ICU admission scores, and careful consideration of confounders, eg, severity of TR and type of surgery. Furthermore, surrogates of RV function improve established risk prediction models reflected by a substantial improvement of the discriminatory power and individual risk stratification for both short-term and long-term mortality.

Prognostic Value of LV Morphology and Function

The prognostic importance of LVEF before cardiac surgical procedures has been shown in several studies for a variety of cardiac diseases and has therefore been incorporated in risk stratification tools such as the EuroSCORE. Thus, several studies have investigated the impact of LV function before ECMO initiation on outcome. Most recently only 1 out of 4 studies that investigated EF before postcardiotomy ECMO initiation found a significant difference in EF between survivors and nonsurvivors. Interestingly, in this study, the predominant surgical procedure before ECMO initiation was isolated coronary artery bypass graft surgery as opposed to others where valve procedures were more prevalent. A major limitation of EF is the diversity of pathologies that influence this parameter. It grossly underestimates the extent of myocardial impairment, particularly in patients with concomitant left-sided regurgitant valve lesions. Indeed, for a given contractility a significantly increased preload and reduced afterload (a common finding in mitral and aortic regurgitation) will yield a normal-appearing EF despite intrinsic myocardial damage, dysfunction, and reduced output. The heterogeneity of the cohort in the present and other studies therefore makes it almost impossible to predict outcomes by preoperative EFs. Furthermore, the sample size in the study by Hsu et al was relatively small ($n=51$), and the regression analysis was adjusted only for the chronic heart failure stage and preoperative hypotension. Rastan and co-workers also detected no difference in EF between survivors and nonsurvivors in a large cohort ($n=517$) of patients who were in need of ECMO after cardiac surgery. Other contemporary studies that investigated precardiotomy EF as a predictor of outcome were underpowered and lacked multivariable regression analyses. A probable limitation of the EF is its operator dependency and mistakes due to endocardial delineation errors. We therefore also investigated a new index of LV function—peak systolic LV strain—measured by an automated speckle-tracking algorithm, which previously has been shown to be a more sensitive marker of intrinsic myocardial dysfunction, albeit subject to similar limitations as EF such as
Prognostic Value of RV Function

RV function may be impaired in a variety of cardiovascular and pulmonary disease states with chronic left-sided heart failure being the most common. Both pathophysiological and prognostic significance of the right heart and pulmonary circulation have been underestimated in the past but more recently have been recognized to be of crucial prognostic significance. The same is true in postcardiotomy ECMO support: although preoperative LV function has been studied extensively, the role of RV function and pulmonary circulation remains unknown. The incidence of right heart failure following cardiotomy is relatively low, ranging from 0.04% to 1% depending on the study. However, with more heterogeneous cohorts, a relative increase can be observed. In particular, recipients of LV assist devices are susceptible to refractory right heart failure, which occurs in up to 30%. Similar hemodynamic concepts apply to patients receiving ECMO support after pericardiotomy: altered interventricular balance introduces a hemodynamic load shift toward the pulmonary circulation and the right heart. We show—for the first time—a high incidence of RV impairment in this vulnerable patient cohort and its prognostic significance. Of note, metrics of RV function were strong predictors of outcome, univariate and after comprehensive adjustment for clinical variables and confounders. The major advantage of RV strain and TAPSE, as opposed to fractional area change, is that they purely reflect the RV function without integrating the interventricular septum. Furthermore, there is less likelihood of endocardial delineation error, a common source of error in volumetric or area measurements. Anatomic features, eg, prominent trabeculation of the right heart, add complexity to endocardial border delineation. TAPSE is a powerful, fast, and easily obtainable measurement. However, a major limitation of this measure is that it is obtained at only 1 single region of interest—the lateral tricuspid annulus. In contrast, RV strain tracks speckles throughout the entire lateral wall of the right heart, reflecting more specifically the myocardial fiber contractility. Our results suggest that ideally RVLS should be used to predict outcome and improve currently established risk prediction model scores. However, given the limitations of nonavailability of speckle-tracking software in some hospitals and the lack of standardization between vendors, alternative surrogate markers of RV function such as TAPSE, semiquantitative assessment by an experienced reader, or an integrated approach seem to be valid alternatives to estimate RV function and enhance risk stratification.

We also investigated more experimental metrics of RV function that have shown to be predictive in mechanical circulatory support patients. We calculated the RV contraction pressure index as a surrogate for the RV stroke-work index and the RV to LV diameter ratio. Those parameters were not significantly predictive of outcome. The major limitations of the calculated values are their susceptibility to measurement errors. Ratios introduce an additional possible error by combining 1 or more measurements. This might particularly bias the RV to LV diameter ratio as well as area measurements of the right heart. The right heart is a complex 3-dimensional structure, and a single diameter might not adequately reflect the size. The estimated pulmonary pressures from the tricuspid regurgitation velocities that are incorporated into the RV contraction pressure index to estimate RV stroke-work index might bias this particular measurement because they are dependent on right heart function and on the gradient between the RV and the right atrium, which might lead to gross underestimations of systolic pulmonary pressures and hence bias of the calculated measurements.

The presence of TR may mask reduced RV function just as mitral regurgitation may mask reduced LV performance. Indeed, significant TR was highly prevalent in this series (TR ≥ moderate in 39% of the patients). Kammerlander and co-workers recently proved that there was no significant association between TR and outcome in a prospective cohort late after left-sided heart valve surgery and pointed out the prognostic importance of RV function. Similarly, in the present study, TR is rather a consequence of RV dysfunction and increased afterload than the primary culprit.

In this series we show the crucial role of RV function in patients receiving ECMO support after pericardiotomy. Our data indicate that patients in need of ECMO after pericardiotomy have a limited prognosis if RV function is already impaired preoperatively. Whether the dismal clinical course can be altered by specific interventions remains to be demonstrated. Potential strategies to alleviate the impact of reduced RV function on outcome might include (1) avoiding open heart surgery—eg, showing a preference for minimally invasive/transcatheter approaches; (2) optimizing inotropic treatment; (3) use of pulmonary vasodilators; (4) early use of biventricular assist devices; and (5) prompt evaluation of candidates for high-urgency heart transplant.

Strengths and Limitations

Echocardiographic data were available for only a relatively small subset of patients. However, there were no significant differences in baseline characteristics between patients who
underwent comprehensive examinations at our institution before ECMO therapy and those with extramural reports, and so far, this is the first study with thorough analyses of biventricular morphology and function in patients subsequently receiving ECMO support. Although comparable mortality rates suggest similar morbidity, we cannot rule out some degree of selection bias. There is always an element of inter- and intraobserver variability, but we demonstrate it to be within an acceptable range given the presence of experienced readers.

Conclusions
In this series of patients on ECMO support, RV function before cardiac surgery is a strong and independent predictor of both short-term and long-term mortality. The results suggest that RV function assessed by echocardiography improves the predictive power of the currently used risk prediction models. Finally, peak systolic strain of the lateral RV free-wall might best reflect intrinsic RV contractile fiber dysfunction, but TAPSE or semiquantitative assessment by experienced readers might be valid alternatives if speckle-tracking software is not available. Further studies are needed to assess the possible treatment strategies to support the right heart in patients in need of ECMO support.

Sources of Funding
This work was supported by an Erwin-Schrödinger Stipend (FWF Austrian Science Fund).

Disclosures
None.

References
1. Bartlett RH, Roloff DW, Custer JR, Younger JG, Hirsch RB. Extracorporeal life support: the University of Michigan experience. JAMA. 2000;283:904–908.
2. Rastan AJ, Dege A, Mohr M, Doll N, Falk V, Walther T, Mohr FW. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiomyopathy cardiogenic shock. J Thorac Cardiovasc Surg. 2010;139:302–311.e1.
3. Smedira NG, Blackstone EH. Postcardiomyopathy mechanical support: risk factors and outcomes. Ann Thorac Surg. 2001;71:S60–S66; discussion S82-S85.
4. Combes A, Leprince P, Luyt CE, Bonnet N, Trouillet JL, Leger P, Pavie A, Chastre J. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiac shock. Crit Care Med. 2008;36:1404–1411.
5. Bakhtiary F, Keller H, Dogan S, Dzemali O, Oezaslan F, Meininger D, Ackermann H, Zwissler B, Kleine P, Moritz A. Venoarterial extracorporeal membrane oxygenation for treatment of cardiac shock: clinical experiences in 45 adult patients. J Thorac Cardiovasc Surg. 2008;135:382–388.
6. Doll N, Kaisi B, Borger M, Bucerius J, Kramer K, Schmitt DV, Walther T, Mohr FW. Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock. Ann Thorac Surg. 2004;77:151–157; discussion 157.
7. Fiser SM, Tribble CG, Kaza AK, Long SM, Zacour RK, Korn JA, Kron IL. When to discontinue extracorporeal membrane oxygenation for postcardiomyopathy support. Ann Thorac Surg. 2001;71:210–214.
8. Ko WJ, Lin CY, Chen RJ, Wang SS, Lin FY, Chen YS. Extracorporeal membrane oxygenation support for adult postcardiomyopathy cardiogenic shock. Ann Thorac Surg. 2002;73:538–545.
9. Magovern GJ Jr, Simpson KA. Extracorporeal membrane oxygenation for adult cardiac support: the Allegheny experience. Ann Thorac Surg. 1999;68:655–661.
10. Pagani FD, Aaronson KD, Swaniker F, Bartlett RH. The use of extracorporeal life support in adult patients with primary cardiac failure as a bridge to implantable left ventricular assist device. Ann Thorac Surg. 2001;71:277–S81; discussion S82-S85.
11. Rastan AJ, Lachmann N, Walther T, Doll N, Gradistanec T, Gomert JP, Lehmann S, Wittekind C, Mohr FW. Autopsy findings in patients on postcardiomyopathy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs. 2006;29:1121–1131.
12. Smith C, Bellomo R, Raman JS, Matalanis G, Rosalon A, Buckmaster J, Hart G, Silvester W, Gutteridge GA, Smith B, Doolan L, Buxton BA. Extracorporeal membrane oxygenation-based approach to cardiogenic shock in an older population. Ann Thorac Surg. 2001;71:1421–1427.
13. Zhang R, Kofidis T, Kamiya H, Shrestha M, Tessmann R, Haverich A, Klima U. Creatine kinase isoenzyme MB relative index as predictor of mortality on extracorporeal membrane oxygenation support for postcardiomyopathy cardiogenic shock in adult patients. Eur J Cardiothorac Surg. 2006;30:617–620.
14. Distelmaier K, Niessen A, Haider D, Lang IM, Heinz G, Maurer G, Koing H, Steinlechner B, Goliasch G. Long-term mortality in patients with chronic obstructive pulmonary disease following extracorporeal membrane oxygenation for cardiac assist after cardiovascular surgery. Intensive Care Med. 2013;39:1444–1451.
15. Distelmaier K, Roth C, Binder C, Schrutka B, Schreiber C, Hoffelner F, Heinz G, Lang IM, Maurer G, Koing H, Steinlechner B, Niessen A, Goliasch G. Urinary output predicts survival in patients undergoing extracorporeal membrane oxygenation following cardiovascular surgery. Crit Care Med. 2016;44:531–538.
16. Distelmaier K, Winter MP, Rutzler K, Heinz G, Lang IM, Maurer G, Koing H, Steinlechner B, Niessen A, Goliasch G. Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery. Crit Care. 2014;18:R24.
17. Hsu PS, Chen JL, Hong GJ, Tsai YT, Lin CY, Lee CY, Chen YG, Tsai CS. Extracorporeal membrane oxygenation for refractory cardiogenic shock after cardiac surgery: predictors of early mortality and outcome from 51 adult patients. Eur J Cardiothorac Surg. 2010;37:328–333.
18. Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: I. Anatomy, physiology, and assessment. Anesth Analg. 2009;109:407–421.
19. Maslow AD, Regan MM, Panzica P, Heindel S, Mashikian J, Comunale ME. Precardiopulmonary bypass right ventricular function is associated with poor outcome after coronary artery bypass grafting in patients with severe left ventricular systolic dysfunction. Anesth Analg. 2002;95:1507–1518, table of contents.
20. Ochiai Y, McCarthy PM, Smedira NG, Banbury MK, Navia JL, Fong J, Hsu AP, Yeager ML, Buda T, Hoercher KJ, Howard MW, Takagaki M, Doi K, Fukamachi K. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation. 2002;106:1198–1202.
21. Pinzani A, de Gevigney G, Pinzani V, Ninet J, Milon H, Delahaye JP. [Pre- and postoperative right heart insufficiency in patients with mitral or mitral-aortic valve diseases]. Arch Mal Coeur Vaiss. 1993;86:27–34.
22. Reichert CL, Visser CA, van den Brink RB, Koolen JJ, van Wezel HB, Mouljin AC, Dunning AJ. Prognostic value of biventricular function in hypertensive patients after cardiac surgery as assessed by transesophageal echocardiography. J Cardiothorac Vasc Anesth. 1992;6:429–432.
23. Assanelli D, Lew WY, Shabetari R, LeWinter MM. Influence of the pericardium on right and left ventricular filling in the dog. J Appl Physiol. 1987;63:1025–1032.
24. Kempny A, Diller GP, Kaleschke G, Orawt S, Funke A, Schmidt R, Kerckhoff G, Ghezelbash F, Rukosujew A, Reinecke H, Scheld HH, Baumgartner H. Impact of transseptal catheter-aortic valve implantation or surgical aortic valve replacement on right ventricular function. Heart. 2012;98:1299–1304.
25. Davidson MJ. Can the off-pump coronary artery bypass debate shed light on postoperative right heart dysfunction? Circulation. 2008;117:2181–2183.
26. Burkhoff D, Sayer G, Doshi D, Uriel N. Hemodynamics of mechanical circulatory support. J Am Coll Cardiol. 2015;66:2663–2674.
27. Kapur NK, Esposito M. Hemodynamic support with percutaneous devices in patients with heart failure. Heart Fail Clin. 2015;11:215–230.
28. Kapur NK, Zisa DC. Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) fails to solve the haemodynamic support equation in cardiogenic shock. EuroIntervention. 2016;11:1337–1339.
29. KAUL TK, FIELDS BL. Postoperative acute refractory right ventricular failure: incidence, pathogenesis, management and prognosis. Cardiovasc Surg. 2000;8:1–9.

30. HADDAD F, DAUDELAY AY, COURTOUR P, CARTIER R, PELLERIN M, LEVEQUE S, LAMBERT J, TARIDF JC. Right ventricular myocardial performance index predicts perioperative mortality or circulatory failure in high-risk valvular surgery. J Am Soc Echocardiogr. 2007;20:1065–1072.

31. NAGEL E, STUBER M, HESS OM. Importance of the right ventricle in valvular heart disease. Eur Heart J. 2001;22:829–836.

32. SACHDEV A, VILLARRAGA HR, FRANTZ RP, MCGOON MD, HSJAO HF, MAALOUF JF, AMMASH NM, MCCULLY RB, MILLER FA, PELLIKKA PA, OH JK, KANE GC. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest. 2011;139:1299–1309.

33. AISSAOUI N, SALEM JE, PALUSZKIEWICZ L, MORKHUIS M, GREORI G, FAGON JY, GUMMERT J, DIEBOLD B. Assessment of right ventricular dysfunction predictors before the implantation of a left ventricular assist device in end-stage heart failure patients using echocardiographic measures (ARVADE): combination of left and right ventricular echocardiographic variables. Arch Cardiovasc Dis. 2015;108:300–309.

34. GANT AD, SMEDIRA NG, STARLING RC, MARWICK TH. Independent and incremental role of quantitative right ventricular evaluation for the prediction of right ventricular failure after left ventricular assist device implantation. J Am Coll Cardiol. 2012;60:521–528.

35. FINE NM, CHEN L, BASTIANSEN, FRANTZ RP, PELLIKKA PA, OH JK, KANE GC. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging. 2013;6:711–721.

36. ORDE SR, PULIDO JN, MASAKI M, GILLESPIE S, SPOON JN, KANE GC, OH JK. Outcome prediction in sepsis: speckle tracking echocardiography based assessment of myocardial function. Crit Care. 2014;18:R149.

37. LANG RM, BADANO LP, MOR-AVI V, AFFALIO J, ARMSTRONG A, EMANDE L, FLAHERTY FA, FOX J, KUZNETSOVA T, LANCELLOTTI P, MURARU D, PICARD MH, RIEZTSCHEL ER, RUDSKI L, SPENCER KT, TSANG W, VOIGT JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the American College of Cardiology. J Am Soc Echocardiogr. 2015;28:1–39.614.

38. RUDSKI LG, LAI WW, AFFALIO J, HUA L, HANDSCHUMACHER MD, CHANDRASEKARAN K, SOLONOM SD, LOUIE EK, SCHILLER NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2013;26:1–39.614.

39. RUDSKI LG, LAI WW, AFFALIO J, HUA L, HANDSCHUMACHER MD, CHANDRASEKARAN K, SOLONOM SD, LOUIE EK, SCHILLER NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2013;26:1–39.614.

40. LANG RM, BADANO LP, MOR-AVI V, AFFALIO J, ARMSTRONG A, EMANDE L, FLAHERTY FA, FOX J, KUZNETSOVA T, LANCELLOTTI P, MURARU D, PICARD MH, RIEZTSCHEL ER, RUDSKI L, SPENCER KT, TSANG W, VOIGT JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the American College of Cardiology. J Am Soc Echocardiogr. 2015;28:1–39.614.

41. GANT AD, SMEDIRA NG, STARLING RC, MARWICK TH. Independent and incremental role of quantitative right ventricular evaluation for the prediction of right ventricular failure after left ventricular assist device implantation. J Am Coll Cardiol. 2012;60:521–528.

42. FINE NM, CHEN L, BASTIANSEN, FRANTZ RP, PELLIKKA PA, OH JK, KANE GC. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging. 2013;6:711–721.

43. ORDE SR, PULIDO JN, MASAKI M, GILLESPIE S, SPOON JN, KANE GC, OH JK. Outcome prediction in sepsis: speckle tracking echocardiography based assessment of myocardial function. Crit Care. 2014;18:R149.

44. LANG RM, BADANO LP, MOR-AVI V, AFFALIO J, ARMSTRONG A, EMANDE L, FLAHERTY FA, FOX J, KUZNETSOVA T, LANCELLOTTI P, MURARU D, PICARD MH, RIEZTSCHEL ER, RUDSKI L, SPENCER KT, TSANG W, VOIGT JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the American College of Cardiology. J Am Soc Echocardiogr. 2015;26:1–39.614.

45. RUDSKI LG, LAI WW, AFFALIO J, HUA L, HANDSCHUMACHER MD, CHANDRASEKARAN K, SOLONOM SD, LOUIE EK, SCHILLER NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2013;26:1–39.614.

46. RUDSKI LG, LAI WW, AFFALIO J, HUA L, HANDSCHUMACHER MD, CHANDRASEKARAN K, SOLONOM SD, LOUIE EK, SCHILLER NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2013;26:1–39.614.
SUPPLEMENTAL MATERIAL
Figure S1. Flow diagram. Of 240 patients who received a VA-ECMO after cardiotomy at the Vienna General Hospital, 56 were excluded because they underwent cardiac transplantation. In the remaining cohort of 189 patients echo images were available in 111 patients.